Small development-stage biotech with ample cash and a partnership with Sanofi. Heart disease focus with initial compound entering Phase 3 trials. No immediate catalysts, but looks like a decent technical setup. Momentum leader that has quadrupled over the past year, currently in a meaningful pullback.
Ideally would like to see it test the Feb lows and rising trend support around 47.50. But if it's strong out of the gate tomorrow, I might just buy in.
Trade active
⋅
Did buy in, as the stock is really strong out of the gate.
Comment
⋅
Been a long time. But for those that are still in or interested, I think it once again sets up well.
Looks good.